News Sentiment

ALMS sentiment intelligence

Alumis Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 59 Balanced news tone 61 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 23.41 Week of 19 Jun 2026
Weighted tone 59/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

75/100 classification confidence.

Company focus 54

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend active

-3.1% over one week, +6.3% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

Alumis | 4: Statement of changes in beneficial ownership of securities-10% Owner Foresite Capital Management VI LLC

Market Reaction

Balanced read

67/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 75/100 classification
One-week reaction -3.1% Price reacting lower
Trend fit Trend active 6.3% over four weeks
Fair value 107.0% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 28
Neutral 29
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 54
Industry context 7
Sector context 0

Sources

Coverage mix

Publishers
Market source 13
Stock Titan 8
simplywall.st 5
Moomoo 4
GuruFocus 3
Quiver Quantitative 3
TradingKey 2
Simply Wall Street 2

Event Lens

What the news is about

Classified themes
Market update 25
Earnings 22
Analyst action 10
Regulatory and legal 3
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 61
Investing.com Direct company coverage

Stifel reiterates Alumis stock rating on psoriasis trial data

Stifel maintained a Buy rating and a $44.00 price target for Alumis Inc (ALMS) after the company's first-quarter 2026 update and positive Phase 3 data for its TYK2 inhibitor, envudeucitinib, in psoriasis. The firm highlighted that the data for envudeucitinib were comparable to or

Tone
Positive 71/100
Event
Analyst action
Published
15 May 2026 13:09
Source
Investing.com
Benzinga Direct company coverage

This Alumis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

This article details the top five analyst downgrades on Friday, May 15, 2026. Alumis Inc. (NASDAQ: ALMS) saw its rating cut from Buy to Neutral, while Tango Therapeutics (NASDAQ: TNGX), Viking Holdings (NYSE: VIK), Aardvark Therapeutics (NASDAQ: AARD), and A.O. Smith Corp (NYSE:

Tone
Neutral 50/100
Event
Analyst action
Published
15 May 2026 12:09
Source
Benzinga
Investing.com Direct company coverage

Guggenheim raises Alumis stock price target to $34 on psoriasis data

Guggenheim has increased its price target for Alumis Inc (NASDAQ:ALMS) to $34 from $32 and maintained a Buy rating, following positive first-quarter earnings and promising clinical trial updates for its oral TYK2 inhibitor, envudeucitinib, in psoriasis. The company's stock has se

Tone
Positive 85/100
Event
Analyst action
Published
15 May 2026 07:31
Source
Investing.com
Stock Titan Direct company coverage

Alumis psoriasis pill hits 68% PASI 90 in Phase 3 trial

Alumis (NASDAQ: ALMS) reported its Q1 2026 financial results, including a net loss of $93.1 million and cash reserves of $569.5 million, which are expected to fund operations into Q4 2027. The company highlighted strong Phase 3 clinical data for its psoriasis treatment, envudeuci

Tone
Positive 72/100
Event
Earnings
Published
14 May 2026 20:40
Source
Stock Titan